Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

36.88 +0.12 (+0.33%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Avoid These 7 Stocks in Retirement Like the Plague
By, Bob Ciura Investors who are in retirement, or nearing retirement will have different needs than their younger counterparts still in the accumulation phase of their life.... 
Via Benzinga
Topics Retirement
Exposures Pension
Alector Stock Falls After Flashing 12-Month Data From Mid-Stage Trial In Frontotemporal Dementia Patients
Alector Inc (NASDAQ: ALEC) detailed early data from its lead drug, AL001, INFRONT-2 Phase trial at the Alzheimer's Association International Conference (AAIC... 
Via Benzinga
3 Best Dividend Stocks To Buy With Yields Of More Than 5%
Dividend paying companies with stable fundamentals are prominent bets now considering the market’s high volatility. Established stocks AT&T Inc., Vale S.A, and GlaxoSmithKline, each currently yield... 
Via Talk Markets
Full News Day
The US greatly increased its exports of liquified natural gas in the first half-year, to 9.6 billion cubic feet per day, a rise of 42% from a year earlier. 
Via Talk Markets
Topics Energy
Exposures Fossil Fuels
GlaxoSmithKline plc (GSK) Q2 2021 Earnings Call Transcript
GSK earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Vaccine Demand Boosts GlaxoSmithKline's Q2 Sales, Earnings; Maintains FY21 Guidance
GlaxoSmithKline Plc's (NYSE: GSK) turnover was £8.1 billion in Q2, up 6% Y/Y (actual exchange rate AER), 15% (constant exchange rate CER). Pharmaceuticals... 
Via Benzinga
European Commission To Procure 220K Doses Of Glaxo-Vir Biotech's COVID-19 Antibody
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of... 
Via Benzinga
Exposures COVID-19
Banned Merger
Today stock markets are in disarray after the full horror of Beijing's attack on Chinese capitalism has been understood. 
Via Talk Markets
Understanding GlaxoSmithKline's Unusual Options Activity
On Tuesday, shares of GlaxoSmithKline (NYSE:GSK) saw unusual options activity. After the option alert, the stock price moved up to $39.48. Sentiment: BULLISH Option Type: SWEEP... 
Via Benzinga
Unusual Options Activity Insight: GlaxoSmithKline
On Monday, shares of GlaxoSmithKline (NYSE:GSK) saw unusual options activity. After the option alert, the stock price moved down to $39.13. Sentiment: BEARISH Option Type: SWEEP... 
Via Benzinga
Joblessness Surprise
Despite higher production for the Emirates the price of oil rose sharply today. More output should cut prices. 
Via Talk Markets
Analyzing GlaxoSmithKline's Unusual Options Activity
On Wednesday, shares of GlaxoSmithKline (NYSE:GSK) saw unusual options activity. After the option alert, the stock price moved up to $39.33. Sentiment: BEARISH Option Type:... 
Via Benzinga
Don't Buy These 16 Investments In Retirement
Nearing retirement, or retired? Here are 16 investments to steer clear of. 
Via Talk Markets
Topics Retirement
Exposures Pension
EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine
EMA's human medicines committee has kicked off a rolling review of a COVID-19 vaccine from Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (... 
Via Benzinga
Exposures COVID-19
Weak Week
Friday tried a recovery because retail sales data for June were strong, particularly in dining out, although in the end, the weak tech side cut the optimism. 
Via Talk Markets
GlaxoSmithKline's Anemia Candidate Shows Promise In Late-Stage Studies
GlaxoSmithKline Plc (NYSE: GSK) said its anemia drug for patients with chronic kidney disease succeeded in five late-stage trials. The drug, daprodustat, an oral... 
Via Benzinga
GSK To Sell One-Third Of Its UK R&D Site For £400M
GlaxoSmithKline plc (NYSE: GSK) is planning to sell more than one-third of its 92-acre R&D site in Stevenage, the U.K. The Company is looking to sell 33... 
Via Benzinga
Moderna Is Now More Valued Than Gilead, GlaxoSmithKline: How Long Did COVID-19 Vaccine Maker Take To Hit $100B?
Moderna Inc (NASDAQ: MRNA) stock is on a roll, with its vaccine-induced momentum spilling over into 2021. The Massachusetts-based company, which had a modest beginning... 
Via Benzinga
Exposures COVID-19
Dialing For Stocks
Thanks to Fed Chairman Powell, markets brushed off worrying about inflation today. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
5 French Stocks To Consider For Bastille Day
Bastille Day is France’s National Day, celebrating the Storming of the Bastille on July 14, 1789, a key turning point in the French Revolution. And while the French concept... 
Via Benzinga
Yellow Card
The price of oil fell about 1% today. 
Via Talk Markets
The Past Week's Notable Insider Buys Include Krispy Kreme, Biotechs, SPACs And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Initial and secondary public offerings enticed insiders to... 
Via Benzinga
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback... 
Via Benzinga
A Look Into GlaxoSmithKline's Price Over Earnings
Looking into the current session, GlaxoSmithKline Inc. (NYSE:GSK) is trading at $39.92, after a 0.80% drop. Over the past month, the stock decreased by 0.78%, but over the... 
Via Benzinga
Sanofi, GSK Get Nod For Late-Stage COVID-19 Vaccine Trial In India
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) have received approval from the Drug Controller General of India (DCGI) for a late-stage... 
Via Benzinga
Exposures COVID-19
COVID-19 Vaccine-Induced Blood Clots Probably Linked To Amino Acids, Study Shows: WSJ
Researchers have pointed a handful of amino acids targeted by key antibodies of some people who received the AstraZeneca plc's (NASDAQ: AZN) COVID-19 vaccine... 
Via Benzinga
Exposures COVID-19
Nvidia Launches Supercomputer To Help Advance Fields Of Digital Biology, Genomics
Chip supplier Nvidia Corp (NASDAQ: NVDA) on Tuesday launched Cambridge-1, which it claims is the fastest supercomputer in the United Kingdom, dedicated to the healthcare industry... 
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
Why Alector Zoomed 12% Higher Today
The company has yet another fine July trading day thanks to a Citigroup analyst. 
Via The Motley Fool
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,... 
Via Talk Markets
Exposures COVID-19 Product Safety
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.